Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Biologics to Build Biomanufacturing Facility in Ireland

publication date: Apr 30, 2018

WuXi Biologics is to invest $392 million to build a new biologics drug substance manufacturing facility in Ireland. The new facility will use single-use bioreactors for commercial biomanufacturing. This is also WuXi Biologics’ first manufacturing site outside of China. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will be installed. This facility will create approximately 700 jobs during its construction and over 400 highly skilled jobs after establishment over 5 years. More details....

Stock Symbol: (HKEX: 2269)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital